undamentalytics Newsletter
Sign in

Summit Therapeutics Inc. key statistics and ratios

In fiscal 2024, Summit Therapeutics Inc. had return on equity of -94.9%, debt equal to 0.0% of equity and a current ratio of 10.15. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Jan 20162017Jan 20172018Jan 20182019Jan 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 2024
Operating margin———9.4%<−999%<−999%<−999%——
Net margin—−927.6%−79.3%19.0%<−999%<−999%<−999%——
Free-cash-flow margin—523.4%−58.6%−61.8%<−999%<−999%<−999%——
Return on equity———40.3%−76.9%−108.9%−75.1%—−94.9%
Return on assets————−51.4%−82.1%−20.3%−141.8%−69.3%
Asset turnover————0.010.020.00——
Current ratio————4.413.8016.939.3010.15
Debt to equity———0.0%0.0%0.0%406.1%128.7%0.0%
Interest cover (operating income ÷ interest)———8.7xn/mn/mn/mn/mn/m
Effective tax rate———−19.7%—————
R&D as % of revenue———91.1%>999%>999%>999%——
Capital spending as % of revenue—3.5%1.4%0.3%49.0%16.9%88.5%——
Free cash flow ÷ net income———−324.4%—————
Dividends ÷ net income———0.0%—————

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $752m
Short-term assets $721mLonger-term assets $32m
What it owes, and who funded it · $752m
Short-term liabilities $104mLonger-term liabilities $19mShareholders' equity $630m
  • Short-term assets cover short-term liabilities $721m of assets due within a year against $104m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $721m short-term assets against $19m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Summit Therapeutics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Summit Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Summit Therapeutics Inc.